More on the News The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels. Price Performance Image Source: Zacks Investment Research Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term g ...

According to the U.S. Census Bureau, the "U.S. population age 65 and over grew nearly five times faster than the total population over the 100 years from 1920 to 2020." Not only that, the older population reached 55.8 million, representing 16.8% of the nation in 2020. Thanks to the post-World War II baby boom, a mass of humanity entered the frame. Brookdale Senior Living (BKD) Still, prospective investors will require some patience. In the past four quarters, the company incurred a loss per share of 19 cent ...

BD BACTEC™ Blood Culture VialsBD BACTEC™ Blood Culture Vials "While this supplier issue is not expected to have a material financial impact on BD, we are fully focused on returning the supply of blood culture vials to normal levels." BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technol ...

FRANKLIN LAKES, N.J., July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1]. This furthers the company's progress toward its goal to reach net zero GHG emis ...

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. The tool is intended to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases. Single-cell studies of various areas of health and disease are currently being conducted by researchers worldwide uti ...

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell multiomic research. Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD R ...

BD will issue a detailed announcement prior to each quarter's webcast, confirming the date and time of the earnings news release and webcast for that quarter. Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m. (ET) Fourth Quarter Fiscal 2024 — Thursday, November 7, 2024 at 8:00 a.m. (ET) Contacts: FRANKLIN LAKES, N.J., June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to disc ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced a definitive agreement to acquire Edwards Lifesciences' (EW) Critical Care product group (Critical Care). The transaction is expected to close before the end of the calendar year 2024, subject to customary regulatory reviews and closing conditions. EW's Critical Care's portfolio includes the gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, non-invasive cuffs, tissue oximetry sensors and monitors. Up ...

Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its solid product portfolio. The optimism led by a solid second-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist. Over the past year, this Zacks Rank #3 (Hold) stock has lost 5.2% against the 4% rise of the industry and 23.3% growth of the S&P 500. The renowned medical technology c ...

FRANKLIN LAKES, N.J., June 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions. BD today announced a defi ...